Keyword: FibroGen

FibroGen’s partner Astellas has reported phase 3 data that could support filings of their HIF inhibitor in Europe as an oral alternative to EPO.

The combined company will own potentially complementary kidney disease drugs and a sales force to promote them.

The ROCK2 inhibitor had a stronger effect on FVC than standard of care, but the lack of detail in the top-line data leave scope for doubts.

Shares in the biotech shot up 60% after it posted phase 2 data that suggest it can muscle in on a market fought over by Boehringer and Roche.

Vifor Pharma has struck a deal to sell Akebia Therapeutics’ phase 3 oral anemia drug vadadustat through its network of U.S. dialysis centers.

Otsuka Pharmaceutical has expanded its anemia pact with Akebia Therapeutics.

FibroGen has posted positive phase 3 data on its AstraZeneca-partnered anemia drug.

AstraZeneca has released $62 million for a license payment to partner FibroGen ($FGEN) as its experimental pill roxadustat continues its late-stage testing for anemia in kidney disease patients.